Table 1.

Wee1 inhibitors in clinical trials.

Study Identifier	Co-Treatment	Tumor Type	Phase	Status
Adavosertib (AZD1775) as Monotherapy
NCT01748825	–	S	1	Complete
NCT03313557	–	S	1	Complete
NCT03668340	–	S	2	Active
NCT03315091	–	S	1	Complete
NCT02659241	–	S	1	Active
NCT03333824	–	S	1	Active
NCT02207010	–	S	0	Complete
NCT04439227	–	S/H	2	Active
NCT02593019	–	S	2	Complete
NCT04590248	–	S	2	Active
NCT03385655	–	S	2	Active
Adavosertib in combination with other cytotoxic therapies
NCT02666950	Cytarabine	H	2	Complete
NCT01164995	Carboplatin	S	2	Active
NCT03012477	Cisplatin	S	2	Complete
NCT02101775	Gemcitabine	S	2	Active
NCT02906059	Irinotecan	S	1	Complete
NCT03330847	Olaparib	S	2	Active
NCT02341456	Carboplatin/Paclitaxel	S	1b	Complete
NCT02508246	Cisplatin/Docetaxel	S	1	Complete
NCT02194829	Gemcitabine/Paclitaxel	S	1, 2	Active
NCT03345784	Cisplatin/RT	S	1	Active
NCT02585973	Cisplatin/RT	S	1	Complete
NCT03028766	Cisplatin/RT	S	1	Complete
NCT02037230	Gemcitabine/RT	S	1, 2	Complete
NCT01849146	Temozolomide/RT	S	1	Active
Other Wee1 inhibitors in clinical testing – Zn-c3
NCT04158336	–	S	1	Active
Other Wee1 inhibitors in clinical testing – IMP7068
NCT04768868	–	S	1	Active
Other Wee1 inhibitors in clinical testing – Debio 0123
NCT03968653	Carboplatin	S	1	Active

Suspended trials were not included in the list. S, solid tumors. H, hematological cancers.